Nuklearmedizin. Nuclear medicineProstatic NeoplasmsMaleZirconiumHumansAnimals
Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO).
Syed Qaiser Shah, Ralph Santos-Oliveira, DeryaIlem Ozdemir, Saba Shirin
Published: 202510.1055/a-2723-3284
Abstract
To develop a site-specifically radiolabeled version of IMMU-132 (sacituzumab govitecan) using zirconium-89 (⁸⁹Zr) with the chelator 3,4,3-LI(1,2-HOPO) and evaluate its stability, specificity, and quantitative targeting ability in TROP-2-positive pros…
Preview only. Read the full abstract at the source